How Sponsors Actually Decide Which Sites Get the Study
Site selection is a risk-avoidance decision, not a search for the highest-potential site. Here is what sponsors and CROs actually evaluate — and what you can fix before the next feasibility questionnaire lands.
By Trialflow Team
Site selection decisions get made by people you often never meet, using documents you fill out in a hurry. Understanding what those people are actually weighing changes how you present yourself — and sometimes changes what you fix internally before the next feasibility arrives.
The decision is mostly about risk, not potential
Sponsors and CROs are not hunting for the site with the highest ceiling. They are trying to avoid the site that activates in month four, enrolls one patient, and absorbs monitoring hours for two years. Every question on a feasibility questionnaire is a proxy for "will this site cost me more than it returns?"
That reframing matters. Promising aggressive enrollment numbers makes you look riskier, not stronger, if nothing in your file supports them. A modest, defensible commitment with evidence behind it reads better than an ambitious one with none.
What they look at first
Past performance in the same indication. Not therapeutic area broadly — indication, and ideally similar protocol design. A site that enrolled well in mild asthma says little about severe eosinophilic asthma with a washout.
Enrollment versus commitment, historically. Many sponsors track whether sites hit what they promised in prior studies. Chronic over-promising follows you between sponsors more than people assume.
Startup cycle time. Days from site selection to first patient in. Contract and budget negotiation lag is visible and widely tracked. Slow legal review is a real reason sites get skipped.
Data quality signals. Query rates, time to query resolution, protocol deviation patterns, and monitoring findings from prior studies. A site that enrolls fast but generates heavy deviations is a known trade-off, and increasingly a disqualifying one.
Retention. Dropout and lost-to-follow-up rates matter enormously in longer studies. Sites that keep participants through week 52 are quietly valuable.
Access to the actual population. Not clinic volume — identifiable, reachable patients meeting the real inclusion criteria. Sponsors have learned to discount "we see 2,000 patients a year" claims.
What they look at that sites underestimate
- Staff stability. Coordinator turnover predicts deviations and slow startup. A site that names the same PI and lead coordinator across several studies reads as lower risk.
- Equipment and capability without workarounds. Needing to send participants off-site for imaging or having no -70°C freezer introduces logistics failure points.
- Responsiveness during feasibility itself. How fast you return the questionnaire, whether your answers are internally consistent, and whether someone picks up the phone are all treated as a preview of study conduct.
- Diversity of enrolled populations. Sponsors face real pressure on representation and increasingly weigh whether your prior enrollment reflected the disease population.
Practical steps before the next feasibility
- Build a one-page site profile per therapeutic area with actual prior enrollment numbers, screen-fail rates, startup cycle times, and retention. Update it quarterly.
- Track your own commitment-versus-actual history so you can speak to it honestly, including where you missed and why.
- Shorten contract turnaround with pre-negotiated language and a named decision-maker. This is often the single fastest improvement available.
- Run realistic counts against the full inclusion and exclusion criteria before answering, not just the primary diagnosis code.
- Answer feasibility within 48 hours even if the answer is "we are not a fit for this one." Declining cleanly builds more credibility than a stretched yes.
The sites that get picked repeatedly are rarely the biggest. They are the ones whose numbers turn out to be true.
Enrolling studies shouldn't be this hard
Trialflow gives research sites one platform for lead management, AI trial matching, and recruitment analytics.
Request a Demo